Scott Rodig
Overview
Explore the profile of Scott Rodig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
7905
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schiantarelli J, Benamar M, Park J, Sax H, Oliveira G, Bosma-Moody A, et al.
Cancer Cell
. 2025 Feb;
43(2):308-316.e6.
PMID: 39933900
Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors (ICIs), most exhibit intrinsic or acquired resistance to these therapies. Here, we compare somatic genomic profiles from...
2.
Shanmugam V, Tokcan N, Chafamo D, Sullivan S, Borji M, Martin H, et al.
bioRxiv
. 2025 Feb;
PMID: 39896575
A key challenge in cancer research is to identify the secreted factors that contribute to tumor cell survival. Nowhere is this more evident than in Hodgkin lymphoma, where malignant Hodgkin...
3.
Cappuzzo F, Ricciuti B, Delmonte A, Bonanno L, Wang X, Lye W, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836372
Background: The role of activating alterations in the MAPK pathway in predicting immunotherapy efficacy in lung squamous cell carcinoma (LSCC) patients is largely unknown. The aims of the randomized, phase...
4.
Ricciuti B, Elkrief A, Lin J, Zhang J, Alessi J, Lamberti G, et al.
JTO Clin Res Rep
. 2024 Oct;
5(9):100675.
PMID: 39399157
Introduction: Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal...
5.
Huffman B, Singh H, Ali L, Horick N, Wang S, Hoffman M, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38272561
Background: Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed....
6.
Katz M, Petroni G, Bauer T, Reilley M, Wolpin B, Stucky C, et al.
J Immunother Cancer
. 2023 Dec;
11(12).
PMID: 38040420
Background: Pancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall...
7.
Hoffman S, Dowrey T, Villacorta Martin C, Bi K, Titchen B, Johri S, et al.
Sci Adv
. 2023 Sep;
9(39):eadd9668.
PMID: 37756410
Neuroendocrine tumors (NETs) are rare cancers that most often arise in the gastrointestinal tract and pancreas. The fundamental mechanisms driving gastroenteropancreatic (GEP)-NET growth remain incompletely elucidated; however, the heterogeneous clinical...
8.
Nyman J, Denize T, Bakouny Z, Labaki C, Titchen B, Bi K, et al.
Cell Rep Med
. 2023 Sep;
4(9):101189.
PMID: 37729872
Clear cell renal cell carcinoma (ccRCC) is molecularly heterogeneous, immune infiltrated, and selectively sensitive to immune checkpoint inhibition (ICI). However, the joint tumor-immune states that mediate ICI response remain elusive....
9.
Giannikou K, Klonowska K, Tsuji J, Wu S, Zhu Z, Probst C, et al.
Histopathology
. 2023 Sep;
83(4):569-581.
PMID: 37679051
Aims: Although TSC1 or TSC2 inactivating mutations that lead to mTORC1 hyperactivation have been reported in hepatic angiomyolipomas (hAML), the role of other somatic genetic events that may contribute to...
10.
Zhao W, Kepecs B, Mahadevan N, Segerstolpe A, Weirather J, Besson N, et al.
bioRxiv
. 2023 Jul;
PMID: 37425718
is the most frequently mutated gene across many cancers and is associated with shorter survival in lung adenocarcinoma (LUAD). To define how mutations affect the LUAD tumor microenvironment (TME), we...